Anti-Mouse IL-2 Antibody (JES6-1A12)
Based on 1 Customer Validation
Anti-Mouse IL-2 Antibody (JES6-1A12) is an anti-mouse IL-2 IgG1 monoclonal antibody. Anti-Mouse IL-2 Antibody (JES6-1A12) can inhibit Treg amplification and enhance Th1 response. Anti-Mouse IL-2 Antibody (JES6-1A12) can form a complex with IL-2 for experimentation. Anti-Mouse IL-2 Antibody (JES6-1A12) can be used for research on infection conditions such as malaria.
For research use only. We do not sell to patients.
- Purity : 99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
|
IL-2 |
In Vitro
Anti-Mouse IL-2 Antibody (JES6-1A12) (0.2 µg/mL, 72 h) significantly inhibits the proliferation of CD4+ T cells in the chronic infection stage, but has no inhibitory effect on the proliferation in the acute infection stage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CD4+ T cells in the spleen of mice on the 4th day after infection
-
Concentration:0.2 µg/mL
-
Incubation Time:72 h
-
Result:Inhibited the proliferation of T cells.
In Vivo
Anti-Mouse IL-2 Antibody (JES6-1A12) (molar ratio of IL-2 to JES6-1A12 = 2:1, i.p., for 3 days) can form a complex with IL-2, significantly increasing the sensitivity of C57BL/6 mice to LPS, inducing the expansion of T cells and increasing the number of CD11b+CD14+ cells in the spleen and blood [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×106 infected red blood cells injected female C57BL/6 mice (6-8 weeks)[1]
-
Dosage:1 mg/mouse/day
-
Administration:Intraperitoneal injection (i.p.), on day 0, 2 and 4
-
Result:Effectively inhibited Treg cell expansion without affecting the activation of effector CD4+ T cells or IFN-γ production.
Increased the levels of TNF-α and malaria parasite specific IgG2a antibodies and enhances protective immunity.
Significantly reduced parasitic infections by about 40 %.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo IL-2 neutralization; in vivo IL-2 receptor stimulation (as a complex with IL-2)
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-2 Antibody (JES6-1A12)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zago CA, et al. Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease. PLoS One. 2012;7(1):e29894. [Content Brief]
[2]. Tomala J, et al. IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells. Elife. 2021 Dec 21;10:e62432. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)